Pricing Log in Create free account

Citius Oncology, Inc. (CTOR) vs Zhengye Biotechnology Holding Limited (ZYBT)

Citius Oncology, Inc. and Zhengye Biotechnology Holding Limited are both Drug Manufacturers Specialty & Generic companies. Citius Oncology, Inc. is the larger, with a market value of $46.5M against $41.0M — 1.1× the size. Across the 8 metrics below, Zhengye Biotechnology Holding Limited leads on 7 and Citius Oncology, Inc. on 1.

Valuation

Metric CTOR ZYBT Drug Manufacturers Specialty & Generic median
P/E n/m — 20.55
P/S n/m — 2.08
P/B 1.36 n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales n/m n/m 2.87
Earnings yield (92.16%) — (15.94%)
Free cash flow yield (58.41%) 0.00% 0.00%

Profitability

Metric CTOR ZYBT Drug Manufacturers Specialty & Generic median
Gross margin — — 53.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% — (2.45%)
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (126.58%) 0.00% (0.80%)
Return on assets (45.20%) 0.00% (1.67%)
Return on invested capital (67.15%) 0.00% 0.00%

Growth

Metric CTOR ZYBT Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — — 5.22%
EPS growth (last fiscal year) (9.68%) (800.00%) 42.91%
Revenue growth, 5-year CAGR — — 7.24%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CTOR ZYBT Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.24 0.04
Current ratio 0.73 1.14 2.41
Net debt to EBITDA (0.40) (0.51) 1.01

Dividend

Metric CTOR ZYBT Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric CTOR ZYBT Drug Manufacturers Specialty & Generic median
Market cap 46.50m 41.02m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack